Chris Lange
5 min read
Quick Read
-
Collecting $10,000 annually from BMY requires roughly 3,968 shares and about $252,000 in capital at its current 3.94% yield.
-
Eliquis faces a revenue step-down of between $1.5 billion and $2 billion in 2027 along with U.S. patent expiration in April 2028, threatening the earnings that fund BMY’s dividend.
-
BMY’s Growth Portfolio now drives nearly 60% of revenue and grew 14%, while the stock has surged over 40% in the past year.
-
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Bristol Myers Squibb didn’t make the cut. Enter your email to see the names that beat BMY. The report is free. Enter your email and see if any of your stocks made the cut.
The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live yield and the live payout. That is the only way the number means anything.
Bristol Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines across oncology, hematology, immunology and cardiovascular disease, with headline franchises including Eliquis, Opdivo, Reblozyl, Camzyos, Breyanzi, Opdualag and Cobenfy. It is a large-cap pharma with a market capitalization of roughly $130.0 billion and $49.19 billion in trailing revenue.
Live Math on BMY
The dividend inputs, straight off the tape:
-
Forward annual dividend: $2.52 per share, paid as a $0.63 quarterly.
-
Share price: $63.62 as of September 11, 2026.
-
Dividend yield: 3.94%.
The share count needed for $10,000 in annual income equals the target divided by the per-share dividend ($10,000 / $2.52). The capital required equals that share count multiplied by the current price ($63.62). At the current 3.94% yield, the capital figure lands near a quarter of a million dollars, and the share count sits just under four thousand. Plug in the live quote before you size anything, because both variables move.
Free Report, Just Released
Why Didn’t BMY Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And BMY didn’t make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Enter Your Email and See the Ten →
What This Snapshot Does and Does Not Tell You
